Ribosome S6 Protein Kinase 2 (RSK2) is involved in many signal pathways such as cell growth, proliferation, survival and migration in tumors. Also, RSK2 can phosphorylate YB-1, which induces the expression of tumor initiating cells, leading to poor prognosis of triple negative breast cancer. Herein, phenyl sulfonamide was introduced to a series of 1H-pyrrolo[2,3-b]pyridine-2-carboxamide derivatives to obtain novel RSK2 inhibitors which were evaluated RSK2 inhibitory activity and proliferation inhibitory activity against MDA-MB-468. The newly introduced sulfonamide group was observed to form a hydrogen bond with target residue LEU-74 which played crucial role in activity. The results showed that most of compounds exhibited RSK2 enzyme inhibitory with IC up to 1.7 nM. Compound B1 exhibited the strongest MDA-MB-468 cell anti-proliferation activity (IC  = 0.13 μM). The in vivo tumor growth inhibitory activities were evaluated with compounds B1-B3 in MDA-MB-468 xenograft model which gave up to 54.6% of TGI.

Download full-text PDF

Source
http://dx.doi.org/10.1111/cbdd.14376DOI Listing

Publication Analysis

Top Keywords

1h-pyrrolo[23-b]pyridine-2-carboxamide derivatives
8
phenyl sulfonamide
8
rsk2 inhibitors
8
inhibitory activity
8
rsk2
6
activity
5
synthesis anti-tumor
4
anti-tumor activity
4
activity evaluation
4
evaluation 1h-pyrrolo[23-b]pyridine-2-carboxamide
4

Similar Publications

Ribosome S6 Protein Kinase 2 (RSK2) is involved in many signal pathways such as cell growth, proliferation, survival and migration in tumors. Also, RSK2 can phosphorylate YB-1, which induces the expression of tumor initiating cells, leading to poor prognosis of triple negative breast cancer. Herein, phenyl sulfonamide was introduced to a series of 1H-pyrrolo[2,3-b]pyridine-2-carboxamide derivatives to obtain novel RSK2 inhibitors which were evaluated RSK2 inhibitory activity and proliferation inhibitory activity against MDA-MB-468.

View Article and Find Full Text PDF

Herein we report the synthesis, SAR, and biological evaluation of a series of 1-pyrrolo[2,3-]pyridine-2-carboxamide derivatives as selective and potent PDE4B inhibitors. Compound is a PDE4B preferring inhibitor and exhibited acceptable ADME and significantly inhibited TNF-α release from macrophages exposed to pro-inflammatory stimuli (i.e.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!